NSE filing, NSE: VILAS. Summary written from the filing by ALFA Finder's alert engine.
Vilas Transcore Ltd: key numbers
- Share price
- ₹344.00
- Market cap
- ₹842.1 Cr
- Revenue (annual)
- ₹460.7 Cr
- Net profit (annual)
- ₹39.56 Cr
- P/E (TTM)
- 21.3×Sector 52.8×
- Promoter holding
- 73.14%
- FII holding
- 3.15%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vilas Transcore Ltd
All →Vilas Transcore Annual General Meeting
Vilas Transcore Limited conducted its 20th Annual General Meeting on September 28, 2026. Key business included adopting financial statements and re-appointing directors and auditors.
Vilas Transcore Credit Rating
ICRA reaffirmed Vilas Transcore's bank facility ratings at A-(Stable) and A2+ for limits totalling Rs. 44.98 Crore. The ratings cover cash credit and letter of credit lines from ICICI and HDFC Banks.
Vilas Transcore Product Launch
Vilas Transcore Limited has launched a new line of Paper Covered Copper and Aluminium Conductors. This product expansion enhances its offerings in the transformer components segment.
Vilas Transcore Annual General Meeting
Vilas Transcore Limited issued a notice for its 20th Annual General Meeting scheduled on September 28, 2026, to consider financial statements and director re-appointments.
Vilas Transcore Business Update
Vilas Transcore Limited received manufacturer approval from Power Grid Corporation of India Limited. This enables the company to supply critical components for POWERGRID projects.
Vilas Transcore Results Update
Vilas Transcore's Q1FY27 revenue rose 18.2% to ₹132.4 Crore. The company also acquired land parcels for ₹9.06 Crore to support future manufacturing expansion.
- Value
- ₹9.06 Cr
Other regulatory approval announcements
All →Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.